A Novel Synthetic Lethal Approach to Target MYC-Driven Cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The MYC proto-oncogene family (MYC, MYCL, MYCN) are critical regulators of cancer hallmarks like proliferation and metabolism.
• MYC activation is a frequent event in cancer, driven by various genetic and epigenetic alterations.
• MYC-driven cancers are notoriously difficult to target therapeutically, representing a significant unmet clinical need.

Discussion:

• Sun and colleagues identified a crucial role for CTP synthase 1 (CTPS1), a rate-limiting nucleotide synthesis enzyme, in the survival of MYC-driven cancer cells.
• This study reveals a synthetic lethal strategy combining CTPS1 inhibitors with ataxia telangiectasia and Rad3-related protein (ATR) inhibitors.
• The combination therapy exploits the dependency of MYC-driven tumors on nucleotide synthesis and their sensitivity to DNA replication stress.

Key Insights:

• CTPS1 is essential for the survival of cancer cells driven by MYC.
• A novel synthetic lethal approach involves inhibiting both CTPS1 and ATR to induce cancer cell death.
• This strategy leverages the specific vulnerabilities of MYC-driven cancers to nucleotide depletion and replication stress.

Outlook:

• The findings present promising therapeutic avenues for targeting previously 'undruggable' MYC-driven cancers.
• This research could lead to new treatment strategies for a substantial proportion of human cancers.
• Further investigation into CTPS1 and ATR inhibition combinations may yield effective clinical interventions.